A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma: epidemiology and prognostic factors

Adenoid cystic carcinoma (ACC) accounts for 1% of malignant head and neck tumours [1] and 10% of salivary glands malignant tumours. The main objective of our study is to investigate the prognostic factors influencing the event-free survival (EFS) of patients with ACC. A multicentre prospective study...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cancer 2020-05, Vol.130, p.241-249
Hauptverfasser: Atallah, Sarah, Casiraghi, Odile, Fakhry, Nicolas, Wassef, Michel, Uro-Coste, Emmanuelle, Espitalier, Florent, Sudaka, Anne, Kaminsky, Marie Christine, Dakpe, Stéphanie, Digue, Laurence, Bouchain, Olivier, Morinière, Sylvain, Hourseau, Muriel, Bertolus, Chloé, Jegoux, Franck, Thariat, Juliette, Calugaru, Valentin, Schultz, Philippe, Philouze, Pierre, Mauvais, Olivier, Righini, Christian A., Badoual, Cécile, Saroul, Nicolas, Goujon, Jean Michel, Marie, Jean Paul, Taouachi, Rabah, Brenet, Esteban, Aupérin, Anne, Baujat, Bertrand
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Adenoid cystic carcinoma (ACC) accounts for 1% of malignant head and neck tumours [1] and 10% of salivary glands malignant tumours. The main objective of our study is to investigate the prognostic factors influencing the event-free survival (EFS) of patients with ACC. A multicentre prospective study was conducted from 2009 to 2018. All 470 patients with ACC whose survival data appear in the REFCOR database were included in the study. The main judgement criterion was EFS. Both a bivariate survival analysis using log-rank test and a multivariate using Cox model were performed using the R software. Average age was 55 years. Females accounted for 59.4% of the cohort. The body mass index (BMI) was normal in 86% of cases. Tumours were located in minor salivary glands in 60% of cases. T3/T4 stages represented 58%; 89% of patients were cN0. histological grade III was observed on 21% of patients. The EFS and overall 5-year survival rates were 50% and 85%, respectively. After adjustment, the most significant pejorative prognostic factors were age ≥65 years (hazard ratio [HR] = 1.67), BMI
ISSN:0959-8049
0014-2964
1879-0852
DOI:10.1016/j.ejca.2020.01.023